Monday, September 22, 2008

AstraZeneca Receives Six Months Pediatric Exclusivity for Casodex (bicalutamide) from the FDA

AstraZeneca today announced that the United States Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market CASODEX(R) (bicalutamide) for its licensed advanced prostate cancer indication until April 1, 2009.

The details can be read here.

No comments: